Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash from Operations (2018 - 2025)

Serina Therapeutics' Cash from Operations history spans 8 years, with the latest figure at 3800000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations fell 28.29% year-over-year to 3800000.0; the TTM value through Sep 2025 reached 16452000.0, down 32.39%, while the annual FY2024 figure was 17100000.0, 590.63% down from the prior year.
  • Cash from Operations for Q3 2025 was 3800000.0 at Serina Therapeutics, down from 3778000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 121000.0 in Q4 2023 and bottomed at 8009000.0 in Q2 2024.
  • The 5-year median for Cash from Operations is 1647000.0 (2021), against an average of 2377894.74.
  • The largest annual shift saw Cash from Operations soared 109.16% in 2023 before it crashed 3861.98% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 1647000.0 in 2021, then increased by 19.79% to 1321000.0 in 2022, then surged by 109.16% to 121000.0 in 2023, then plummeted by 3861.98% to 4552000.0 in 2024, then grew by 16.52% to 3800000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Cash from Operations are 3800000.0 (Q3 2025), 3778000.0 (Q2 2025), and 4322000.0 (Q1 2025).